Hansen Pharmaceuticals Co., Ltd.

Announcement on the election of employee representative directors

Legal opinion from Hunan Qiyuan Law Firm regarding the 2025 annual shareholders' meeting of Hunan Hansen Pharmaceutical Co., Ltd.

Announcement of the resolutions of the 2025 annual shareholders' meeting

Announcement on the Proposed Re-appointment of the 2026 Audit Firm

Hunan Hansen Pharmaceutical Co., Ltd. proposes to re-appoint Zhong Shen Zhong Huan Certified Public Accountants (Special General Partnership) as its 2026 audit firm. The decision follows a review by the Audit Committee and Board of Directors, confirming the firm's professional competence, independence, and integrity. The proposed audit fee remains unchanged from the previous period.

2025 Annual Report of Independent Director (Hu Gaoyun)

This report details the independent director's performance in 2025, focusing on fulfilling duties, attending meetings, and reviewing proposals. The director actively participated in board and committee meetings, reviewed financial reports, and engaged with shareholders. The report confirms compliance with independence requirements and highlights the company's support for the director's work, concluding with recommendations for future engagement.

2025 Annual Independent Director Work Report (Zhan Ping)

2025 Annual Report of Independent Director (Xia Song)

This report details the independent director's fulfillment of duties in 2025, focusing on attending board and shareholder meetings, participating in special committee work, and communicating with management and shareholders. The director actively reviewed proposals, supervised financial information, and ensured compliance with regulations, safeguarding shareholder interests. The report confirms no conflicts of interest and adherence to independence requirements.

Internal Control Audit Report for Hunan Hansen Pharmaceutical Co., Ltd.

This report presents the internal control audit for Hunan Hansen Pharmaceutical Co., Ltd. for the year ending December 31, 2025. The audit concludes that the company maintained effective financial reporting internal controls in all material respects. No material weaknesses or significant deficiencies were found in financial or non-financial reporting internal controls.

2025 Annual Internal Control Evaluation Report

This report details the internal control evaluation for Hunan Hansen Pharmaceutical Co., Ltd. as of December 31, 2025. The company found no material weaknesses in financial or non-financial reporting internal controls. The evaluation covered all major units, businesses, and high-risk areas, confirming effective internal control systems.

Compensation and Assessment Management System for Directors and Senior Management

Regulations on Resignation and Dismissal of Directors and Senior Management

This document outlines the procedures and conditions for the resignation and dismissal of directors and senior management of Hunan Hansen Pharmaceutical Co., Ltd. It details the circumstances under which individuals may leave their positions, the required notification periods, and the responsibilities that continue after departure, including confidentiality and non-competition clauses. The regulations aim to ensure stability and protect shareholder interests.

Announcement on the 2026 Salary and Remuneration Plan for Directors and Senior Management

Hunan Hansen Pharmaceutical Co., Ltd. announces its 2026 salary and remuneration plan for directors and senior management. The plan, approved by the board, will be submitted to the 2025 shareholder meeting for approval. It outlines remuneration standards for independent directors, non-independent directors, and senior management, with performance-based components and specific payment methods.

Announcement on Changes to Accounting Policies

Hunan Hansen Pharmaceutical Co., Ltd. announces a change in accounting policies in accordance with new regulations from the Ministry of Finance. The change, effective January 1, 2026, is based on "Enterprise Accounting Standards Interpretation No. 19." The company states this change is reasonable, complies with laws, and will not materially impact its financial position, operating results, or cash flows, nor harm shareholder interests.

Statement and Commitment of Independent Director Candidate

This document is a statement and commitment from Chen Shen, a candidate for independent director of Hunan Hansen Pharmaceutical Co., Ltd. It confirms his understanding of the role, his qualifications, and his commitment to fulfilling his duties independently and in compliance with all relevant laws and regulations. He pledges to uphold the company's interests and his own integrity.

Independent Director Candidate Statement and Commitment

This document is a statement and commitment from Shen Lingfang, a candidate for independent director of Hunan Hansen Pharmaceutical Co., Ltd. The candidate confirms they meet all legal and regulatory requirements for the position, have no conflicts of interest, and understand the duties involved. They pledge to fulfill their responsibilities diligently and ethically.

Statement and Commitment of Independent Director Candidate (Zeng Jianguo)

This document is a statement and commitment from Zeng Jianguo, a candidate for independent director of Hunan Hansen Pharmaceutical Co., Ltd. The candidate confirms they meet all legal and regulatory requirements for the position, have no conflicts of interest, and understand their duties. They pledge to fulfill their responsibilities diligently and independently.

Letter of Commitment to Attend the Latest Independent Director Training

Chen Chen, a nominee for the independent director position at Hunan Hansen Pharmaceutical Co., Ltd., commits to attending the upcoming independent director training. This is required by the Shenzhen Stock Exchange to fulfill independent director duties, as Chen Chen has not yet obtained the recognized qualification certificate. The commitment follows a board resolution and is a prerequisite for the nomination.

Letter of Commitment to Attend the Latest Independent Director Training (Shen Lingfang)

This commitment letter is from Shen Lingfang, a candidate for independent director of Hunan Hansen Pharmaceutical Co., Ltd. As she has not yet obtained the independent director qualification certificate recognized by the Shenzhen Stock Exchange, she commits to attending the upcoming training and obtaining the certificate to fulfill her duties.

Statement and Commitment of Independent Director Nominee

Hunan Hansen Pharmaceutical Co., Ltd. Board of Directors declares its nomination of Chen Shen as an independent director candidate. The nominee has confirmed her qualifications and independence, meeting all legal and regulatory requirements. The nominator commits to ensuring the nominee's compliance and will report any non-compliance.

Independent Director Nominee Statement and Commitment

This document is a statement and commitment from the Hunan Hansen Pharmaceutical Co., Ltd. Board of Directors regarding the nomination of Shen Lingfang as an independent director candidate for the Seventh Board of Directors. The statement confirms that the nominee meets all legal and regulatory requirements for independent director qualifications and independence. It also includes commitments from the nominator regarding the nominee's suitability and actions if independence is compromised.

Statement and Commitment of Independent Director Nominee

This document is a statement and commitment from the Hunan Hansen Pharmaceutical Co., Ltd. Board of Directors regarding the nomination of Zeng Jianguo as an independent director candidate. The nominator confirms the candidate meets all legal and regulatory requirements for an independent director, including independence, qualifications, and absence of disqualifying factors. The nominee also makes commitments regarding their conduct and reporting any conflicts of interest.

Announcement on the Election of the Board of Directors

Hunan Hansen Pharmaceutical Co., Ltd. announces the upcoming election of its 7th Board of Directors. The new board will consist of seven directors, including independent directors. The company has nominated candidates and will hold a shareholder meeting to elect them, with the term of office commencing after the meeting.

Notice of Convening the 2025 Annual Shareholders' Meeting

Hunan Hansen Pharmaceutical Co., Ltd. will hold its 2025 Annual Shareholders' Meeting on May 19, 2026, combining in-person and online voting. The meeting will review the 2025 work report, financial statements, and annual report, and elect new directors and supervisors. Shareholders can register and vote through various methods, including online platforms.

2025 Annual Financial Report

This report presents Hunan Hansen Pharmaceutical Co., Ltd.'s 2025 financial results, audited by Zhonghuan Certified Public Accountants. Key figures show total revenue of 103,875.67 million yuan, a 3.41% increase, and net profit attributable to shareholders of 19,812.04 million yuan, a 10.05% decrease. Total assets grew 5.73% to 269,307.39 million yuan, while total liabilities decreased by 9.22% to 312,150.34 million yuan.

2025 Annual Board Work Report

Announcement on the Resolutions of the Eleventh Meeting of the Sixth Board of Directors

The Board of Directors of Hunan Hansen Pharmaceutical Co., Ltd. held its eleventh meeting, approving the 2025 annual reports, financial statements, and profit distribution plan. Key decisions include a cash dividend of RMB 3 per 10 shares and authorizing the management to apply for bank loans up to RMB 500 million in 2026. The meeting also addressed the election of the seventh board of directors and the reappointment of the auditor.

Announcement on the 2025 Profit Distribution Plan

Hunan Hansen Pharmaceutical Co., Ltd. announces its 2025 profit distribution plan, approved by the board of directors and audit committee. The plan proposes a cash dividend of RMB 3 per 10 shares, totaling RMB 150,960,000.00, based on the total share capital of 503,200,000 shares as of December 31, 2025. This distribution aligns with the company's financial status and future development, meeting legal and charter requirements.

Hunan Hansen Pharmaceutical Co., Ltd. 2026 First Quarter Report

Hunan Hansen Pharmaceutical Co., Ltd. presents its 2026 first-quarter financial report. Key figures show a decrease in operating revenue by 2.25% to RMB 263.23 million, while net profit attributable to shareholders surged by 241.17% to RMB 38.41 million. The company's total assets grew by 1.50% to RMB 2.73 billion.

Hunan Hansen Pharmaceutical Co., Ltd. Goodwill Impairment Test Involving Yunnan Yongzitang Pharmaceutical Co., Ltd. and Yunnan Kangbaijia Pharmaceutical Co., Ltd. Asset Group (Including Goodwill) Recoverable Amount Asset Evaluation Report Due to Financial Report Preparation

2025 Annual Goodwill Impairment Test Report

Report on the Performance Evaluation of the Accounting Firm for the Year 2025

Hunan Hansen Pharmaceutical Co., Ltd. evaluated the performance of Zhongshen Zhonghuan Certified Public Accountants (Special General Partnership) as its 2025 annual report auditor. The firm meets qualification requirements, has a sound quality management system, and provided a comprehensive audit plan. The company concluded that Zhongshen Zhonghuan's performance was compliant, independent, diligent, and accurately reflected the company's financial status.

Report of the Board of Directors' Audit Committee on the Performance of Supervisory Duties Regarding the Accounting Firm for 2025

The Audit Committee of Hunan Hansen Pharmaceutical Co., Ltd. reports on its supervisory duties regarding the accounting firm for 2025. It reviewed the qualifications and performance of Zhongshen Huancai, confirming its suitability and compliance with regulations. The committee communicated with the firm, reviewed audit reports, and found the firm's work to be objective, complete, and timely.

Special Audit Report on the Summary Statement of Non-operating Fund Occupation and Other Related Party Fund Transactions of Hunan Hansen Pharmaceutical Co., Ltd. for 2025

This report provides a special audit opinion on Hunan Hansen Pharmaceutical Co., Ltd.'s 2025 summary statement of non-operating fund occupation and other related party fund transactions. The audit confirms that the statement is consistent with the audited financial statements. The report is intended for the company's 2025 annual report disclosure.

2025 Annual Summary Table of Non-Operating Fund Occupation and Other Related Fund Transactions

Special Report on the Self-Examination of Independent Directors' Independence

2025 Annual Audit Report

2025 Annual Report

Summary of the 2025 Annual Report

Announcement on Using Idle Own Funds for Cash Management